Homogenize and Automatically Classify Cells Obtained During ROSE Procedure

Overview

About this study

The purpose of the study is to prospectively compare the cytology slides (bronchoscopically derived fine needle aspiration samples of lymph nodes and peripheral lung lesions at the time of rapid intraprocedural on-site evaluation (ROSE)) created before and after fully homogenizing the sample obtained during the fine needle aspiration. The secondary objective of the study is to create an artificial intelligence-based classification algorithm that would fully classify the cells present on the cytological slides prepared during the ROSE procedure.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Anyone who is undergoing EBUS procedure for the staging of lung diseases as well as those undergoing navigational bronchoscopy of their peripheral lung lesions.

Exclusion Criteria:

  • < 18 years of age. 
  • Pregnant women (to be screened per institutional standard procedures prior to scheduled clinical procedure)

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 01/03/2025. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Janani Reisenauer, M.D.

Open for enrollment

Contact information:

Thoracic Surgery Research Unit

(877) 526-9172

More information

Publications

Publications are currently not available